Latest Cancer Screening News

Page 1 of 5
BCAL Diagnostics has locked in an additional $4.9 million under its existing convertible note facility alongside a $1.4 million R&D tax offset tranche, reinforcing its funding runway into FY2027 for early cancer detection test development.
Ada Torres
Ada Torres
29 June 2026
TruScreen has secured clinical validation from the world’s largest cervical screening study in China, setting the stage for rapid market expansion across Asia, Africa, and Europe.
Ada Torres
Ada Torres
12 June 2026
4DMedical has leapfrogged into the European lung health market by acquiring Austrian AI imaging firm contextflow, gaining immediate commercial presence and a CE-marked lung cancer screening solution.
Ada Torres
Ada Torres
1 June 2026
TruScreen Group reported a 42% increase in FY2026 sales driven by new market entries including India and Indonesia, alongside launching a large-scale cervical cancer screening program in Vietnam and submitting major UNITAID proposals.
Ada Torres
Ada Torres
29 May 2026
TruScreen Group Limited has kicked off a NZ$2.9 million capital raising combining a NZ$1 million placement and a NZ$1.94 million rights issue to fund its global expansion and regulatory compliance efforts. The company reported a 42% jump in product sales for FY2026 and is targeting major public health programs across 14 countries.
Ada Torres
Ada Torres
21 May 2026
INOVIQ Limited is on track to complete its EXO-OC™ ovarian cancer screening study by mid-2026 and is accelerating its CAR-exosome therapy program, supported by a strong cash position of A$11.9 million.
Ada Torres
Ada Torres
28 Apr 2026
TruScreen Group has met its FY2026 revenue guidance with a 41% jump in product sales, while investing heavily in new markets and pursuing a major UNITAID funding bid that could reshape its medium-term outlook.
Ada Torres
Ada Torres
28 Apr 2026
Tetratherix Limited has raised approximately $5 million to fast-track its Tutelix prostate spacer into pivotal clinical trials across Australia and the US, aiming to improve radiation therapy for prostate cancer patients.
Ada Torres
Ada Torres
10 Mar 2026
A new clinical study from Sichuan University confirms that TruScreen’s AI-enabled cervical cancer screening combined with high-risk HPV testing outperforms traditional cytology methods, reinforcing its global potential.
Ada Torres
Ada Torres
9 Mar 2026
4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.
Ada Torres
Ada Torres
27 Feb 2026
Integral Diagnostics Limited has reported a robust half-year performance, with revenues soaring 55.6% and EBITDA nearly doubling, driven by strong patient volume growth and successful integration of Capitol Health. The company also declared a fully franked interim dividend of 3.3 cents per share.
Ada Torres
Ada Torres
24 Feb 2026
Rhythm Biosciences has inked a non-exclusive distribution agreement with 4Cyte Pathology to integrate its ColoSTAT® colorectal cancer blood test into a vast pathology network across eastern Australia, aiming to boost adoption and accessibility.
Ada Torres
Ada Torres
17 Feb 2026